Chugai Pharmaceutical
Clinical trials sponsored by Chugai Pharmaceutical, explained in plain language.
-
New drug targets immune diseases in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called RAY121 in people with six different immune system diseases, including antiphospholipid syndrome and bullous pemphigoid. The main goal is to check safety and how the body processes the drug. About 144 adults will take part to see if t…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 01:15 UTC
-
New hope for tough lung cancer: early trial of ALPS12 begins
Disease control Recruiting nowThis early-phase study tests a new drug called ALPS12 in about 122 people with extensive-stage small cell lung cancer that has returned after at least one prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Partici…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers: first human trial of AUBE00 begins
Disease control Recruiting nowThis early-stage study tests a new drug called AUBE00 in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must have a …
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New hope for celiac sufferers: drug targets gut damage despite strict diet
Disease control Recruiting nowThis study tests a new drug called DONQ52 in people with active celiac disease who still have intestinal damage and symptoms even after following a gluten-free diet for at least a year. The goal is to see if the drug can heal the small intestine and reduce symptoms like belly pai…
Phase: PHASE2 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated May 01, 2026 16:00 UTC